Prostate Specific Antigen and Gleason Grade: An Immunohistochemical Study of Prostate Cancer-Reference-Cited by-同舟云学术

Prostate Specific Antigen and Gleason Grade: An Immunohistochemical Study of Prostate Cancer

Published:1994-06 Issue:6 Volume:151 Page:1558-1564
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Aihara Masahiro¹,Lebovitz Russell M.¹,Wheeler Thomas M.¹,Kinner Beatriz M.¹,Ohori Makoto¹,Scardino Peter T.¹

Affiliation:

1. From the Matsunaga-Conte Prostate Cancer Research Center, Scott Department of Urology and Department of Pathology, Baylor College of Medicine, The Methodist Hospital and The Houston Veterans Affairs Medical Center, Houston, Texas

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference23 articles.

1. Grading of prostatic carcinoma;Mostofi;Cancer Chemother. Rep.,1975

2. Histologic grading of primary prostatic cancer: a new approach to an old problem;Gaeta;J. Urol.,1980

3. Histologic grading study of prostate adenocarcinoma: the development of a new system and comparison with other methods—a preliminary study;Brawn;Cancer,1982

4. Histologic grading and clinical staging of prostatic carcinoma;Gleason,1977

5. Immunocytochemical localisation of prostate specific antigen: specificity and application to clinical practice;Ford;Brit. J. Urol.,1985

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heterocyclic aromatic amines (HAA), exposure, metabolism, macromolecular adducts, and cancer risk;Encyclopedia of Toxicology;2024

2. Correlation between Pre Biopsy Serum Prostate Specific Antigen Level and Gleason Score in Patients Diagnosed with Prostate Adenocarcinoma: A Hospital Based Study;Pakistan Journal of Health Sciences;2022-12-31

3. Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue;Urology;2022-12

4. Understanding and targeting prostate cancer cell heterogeneity and plasticity;Seminars in Cancer Biology;2021-11

5. Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer;Urologic Oncology: Seminars and Original Investigations;2021-07